Xeris Biopharma Holdings Inc [XERS] stock is trading at $7.59, up 0.26%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The XERS shares have gain 3.97% over the last week, with a monthly amount glided 48.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler downgraded its rating to Neutral on November 11, 2024, and kept the price target unchanged to $3. On March 28, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $5 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $4.50 on August 28, 2023. Jefferies initiated its recommendation with a Buy and recommended $4 as its price target on October 21, 2022. Craig Hallum started tracking with a Buy rating for this stock on April 28, 2022, and assigned it a price target of $6.50. In a note dated November 17, 2021, SVB Leerink initiated an Outperform rating and provided a target price of $6 on this stock.
Xeris Biopharma Holdings Inc [XERS] stock has fluctuated between $2.48 and $7.79 over the past year. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $7.59 at the most recent close of the market. An investor can expect a potential drop of -47.3% based on the average XERS price forecast.
Analyzing the XERS fundamentals
Xeris Biopharma Holdings Inc [NASDAQ:XERS] reported sales of 246.03M for the trailing twelve months, which represents a growth of 48.84%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.04%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is 1.14 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -13.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.49 points at the first support level, and at 7.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.71, and for the 2nd resistance point, it is at 7.83.
Ratios To Look Out For
For context, Xeris Biopharma Holdings Inc’s Current Ratio is 1.95. In addition, the Quick Ratio stands at 1.24 and the Cash Ratio stands at 0.62. Considering the valuation of this stock, the price to sales ratio is 4.98.
Transactions by insiders
Recent insider trading involved JOHNSON JOHN, Director, that happened on Aug 13 ’25 when 0.11 million shares were sold. Director, HALKUFF DAWN completed a deal on Aug 12 ’25 to sell 42500.0 shares. Meanwhile, Director JOHN H JOHNSON bought 0.11 million shares on Aug 13 ’25.
